NERV - Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan Minerva

Minerva Neurosciences management is depleting reserves due to the prolonged approval process for its schizophrenia drug. On GURU.Markets, this quarterly EPS chart demonstrates the results of this strategy, where the value remains at 49.10. The company relies on external CDMO contractors for production, while implementing eco-standards and electronic document management in its laboratories to control biomaterials.

This indicator captures the percentage deviation of current quarter earnings per share relative to the same period last year, allowing for an assessment of corporate development dynamics. By analyzing the quarterly change in earnings per share, a Minerva Neurosciences (NERV) investor will see that in the absence of revenue, the metric reflects only the capital burn rate prior to the delivery of clinical trial results.